| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 4060 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy. Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any developments and will update interested parties as and when the situation changes. |
| 17 March 2022 - 14 April 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 March 2022 | In progress. Scoping commenced |
| 28 January 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual